Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period

Journal of Clinical Virology

Volumn 55, Issue 1, 2012, Pages 72-74

  Del Rosal, Teresa ^a   Baquero Artigao, Fernando ^a   Blázquez, Daniel ^b   Noguera Julian, Antoni ^c   Moreno Pérez, David ^d   Reyes, Alejandro ^e   Vilas, Javier ^f  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF MÁLAGA   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f Complejo Hospitalario de Pontevedra ^*  (Spain)

Author keywords

Congenital cytomegalovirus infection; Hearing loss; Infants; Valganciclovir

Indexed keywords

GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; VALGANCICLOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG TOLERABILITY; EVOKED BRAIN STEM AUDITORY RESPONSE; HEARING LOSS; HEARING TEST; HUMAN; INFANT; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SPAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; GANCICLOVIR; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; NEUTROPENIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865175194     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.06.001     Document Type: Article

References (16)

1. Grosse S.D., Ross D.S., Dollard S.C. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol 2008, 41:57-62.
2. Dollard S.C., Grosse S.D., Ross D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007, 17:355-363.
3. Kimberlin D.W., Lin C., Sánchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003, 143:16-25.
4. Grosse S.D., Dollard S., Ross D.S., Cannon M. Newborn screening for congenital cytomegalovirus: options for hospital-based and public health programs. J Clin Virol 2009, 46:S32-S36.
5. Imamura T., Suzutani T., Ogawa H., Asano K., Nomoto M., Matsui T., et al. Oral valganciclovir treatment for congenital cytomegalovirus infection. Pediatr Int 2011, 53:249-252.
6. National Institute of Allergy and Infectious Diseases website, Division of Microbiology and Infectious Diseases (DMID). Pediatric Toxicity Tables, November 2007. Available at: [accessed 20 July 2011]. http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrc/Documents/dmidpedtox.doc.
7. Baquero-Artigao F y Grupo de estudio de la infección congenita por citomegalovirus de la Sociedad Española de Infectología Pediátrica. Documento de consenso de la Sociedad Española de Infectología Pediátrica sobre el diagnóstico y el tratamiento de la infección congénita por citomegalovirus. An Pediatr (Barc) 2009, 71:535-547.
8. Boppana S.B., Ross S.A., Novak Z., Shimamura M., Tolan R.W., Palmer A.L., et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010, 303:1375-1382.
9. Amir J., Wolf D.G., Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010, 169:1061-1067.
10. Michaels M.G., Greenberg D.P., Sabo D.L., Wald E.R. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 2003, 22:504-509.
11. Meine Jansen C.F., Toet M.C., Rademaker C.M., Ververs T.F., Gerards L.J., van Loon A.M. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med 2005, 33:364-366.
12. Kimberlin D.W., Acosta E.P., Sánchez P.J., Sood S., Agrawal V., Homans J., et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008, 197:836-845.
13. Lombardi G., Garofoli F., Villani P., Tizzoni M., Angelini M., Cusato M., et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009, 28:1465-1470.
14. Clinicaltrials.gov registry. Available at: [accessed 14 May 2012]. http://clinicaltrials.gov/ct2/show/NCT00466817.
15. Baquero-Artigao F., Romero Gómez M.P. Tratamiento prolongado con valganciclovir en un lactante con infección congénita por citomegalovirus. An Pediatr (Barc) 2009, 70:578-581.
16. Sharma A., Campbell J. A sensitive period for cochlear implantation in deaf children. J Matern Fetal Neonatal Med 2011, 24(Suppl. 1):151-153.